The company’s lead candidate, ivonescimab, aimed at treating certain cancers, was discovered by Akeso and is currently in multiple late-stage clinical trials.
The company now expects the health benefits ratio for the full year to be in the range of 88.9% to 89.5%, up from its previous guidance of 88.4% to 89%.
The company’s immunology drugs, Skyrizi and Rinvoq, marked significant revenue growth, offsetting a 50.6% decrease in net revenue from its arthritis drug, Humira.
The company reportedly said the layoffs were meant to help Oculus Studios work more efficiently on future mixed-reality experiences for its growing audience.
Halozyme said that it believes the subcutaneous formulation of Merck's cancer medicine Keytruda infringes multiple patents that Halozyme filed beginning in 2011 to protect its groundbreaking MDASE subcutaneous delivery technology.
CEO Robert Isom highlighted that the airline’s actions over the past several years to refresh its fleet, manage costs, and strengthen its balance sheet position it well for the uncertainty the industry is facing.
CEO Brian L. Roberts highlighted that the company generated $5.4 billion of free cash flow and returned $3.2 billion to shareholders during the quarter.
Chipotle said Trump’s tariffs might raise its cost of sales by about 0.5% this year, which could translate to tens of millions of dollars in extra spending.
Samantha Harris, Tesla's Global Sustainability Lead, was scheduled to speak at the Regenerative Future conference, planned for May 16-17 in Rome by the European Institute of Innovation and Sustainability (EIIS).
The company now expects 2025 revenue to be in the range of $43.3 billion to $44.2 billion and adjusted EPS to be in the range of $21.76 to $22.84, compared with its previous forecast of $23.10 to $23.50.
